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Background: The kidney functions in key physiological processes to filter blood and regulate blood pressure via
key molecular transporters and ion channels. Sex-specific differences have been observed in renal disease incidence
and progression, as well as acute kidney injury in response to certain drugs. Although advances have been made in
characterizing the molecular components involved in various kidney functions, the molecular mechanisms
responsible for sex differences are not well understood. We hypothesized that the basal expression levels of genes
involved in various kidney functions throughout the life cycle will influence sex-specific susceptibilities to adverse
renal events.
Methods: Whole genome microarray gene expression analysis was performed on kidney samples collected from
untreated male and female Fischer 344 (F344) rats at eight age groups between 2 and 104 weeks of age.
Results: A combined filtering approach using statistical (ANOVA or pairwise t test, FDR 0.05) and fold-change
criteria (>1.5 relative fold change) was used to identify 7,447 unique differentially expressed genes (DEGs). Principal
component analysis (PCA) of the 7,447 DEGs revealed sex-related differences in mRNA expression at early (2 weeks),
middle (8, 15, and 21 weeks), and late (104 weeks) ages in the rat life cycle. Functional analysis (Ingenuity Pathway
Analysis) of these sex-different genes indicated over-representation of specific pathways and networks including
renal tubule injury, drug metabolism, and immune cell and inflammatory responses. The mRNAs that code for the
qualified urinary protein kidney biomarkers KIM-1, Clu, Tff3, and Lcn2 were also observed to show sex differences.
Conclusions: These data represent one of the most comprehensive in-life time course studies to be published,
assessing sex differences in global gene expression in the F344 rat kidney. PCA and Venn analyses reveal specific
periods of sexually dimorphic gene expression which are associated with functional categories (xenobiotic
metabolism and immune cell and inflammatory responses) of key relevance to acute kidney injury and chronic
kidney disease, which may underlie sex-specific susceptibility. Analysis of the basal gene expression patterns of
renal genes throughout the life cycle of the rat will improve the use of current and future renal biomarkers and
inform our assessments of kidney injury and disease.
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The kidney functions in the fundamental physiological
processes of filtering waste in the blood and re-absorbing
water and small molecules through specific molecular
transporters. Both endogenous and exogenous metabo-
lites, hormones, and other molecules are handled prima-
rily by proteins in the ATP-binding cassette and solute
carrier super-families. A variety of organic substrates* Correspondence: Joshua.Kwekel@fda.hhs.gov; James.Fuscoe@fda.hhs.gov
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reproduction in any medium, provided the orincluding peptides, nucleosides, drugs, and food consti-
tuents are recognized and transported by these proteins
[1,2]. Homeostatic control of blood pressure is another
key activity of the kidney via sodium-hydrogen ion
exchangers that are regulated by the renin-angiotensin
system [3].
Sex differences have been well established for various
renal diseases, with females generally having protection
compared to males through estrogen’s inhibitory, but an-
drogen’s activating, behaviors on the renin-angiotensin
system [4]. Females generally show lower risk for chronicLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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renal diseases are less prevalent in females; higher risk in
females for diabetic kidney disease has been reported [9].
Diabetic vs. non-diabetic nephropathies present with
conflicting reports from the literature as to their sex-
specificity of injury [3].
Additionally, sex-related differences in acute kidney
injury and nephrotoxicity are also well established,
although heterogeneous in their sex specificity. Many
reports suggest that females show susceptibility to drug-,
diet-, and food supplement-induced renal injury [10-12].
However, male experimental animals have been shown
to be more susceptible to certain metal-induced nephro-
toxicity than females [13]. Females also show protection
against obesity-related adverse renal events due to de-
creased inflammatory response [14] compared to males.
The molecular mechanisms responsible for these sex
differences in adverse events are not well understood.
However, some sex-specific toxicities have been shown
to be related to expression level differences of specific
proteins and transporters. For example, female rats
exhibit sex-specific protection against mercury-induced
nephrotoxicity compared to males [13]. This protection
is conferred to females via the lower expression of
organic anion transporters 1 and 3 (Oat1, Oat3) in the
proximal tubules compared to males, limiting the uptake
of mercury into renal cells and preventing nephroto-
xicity. The sex-specific expression difference of various
proteins and transporters may be responsible for other
sex-related differences in renal disease and injury as well.
Therefore, a better understanding of the basal expression
levels in both male and female animals, across the entire
rat life cycle will provide valuable data for assessing sex
differences in the kidney.
Drug-induced kidney injury is a common reason for
drug candidate failure during drug development [15].
Apart from histopathological evaluations, classical mar-
kers of kidney injury via blood (blood urea nitrogen,
creatinine) and urinary endpoints (color, specific gravity,
and protein levels) are generally considered to be insen-
sitive and non-specific for detecting kidney injury [16].
Collaborative efforts between pharmaceutical and regula-
tory groups and the Predictive Safety Testing Consortium
have led to the evaluation and qualification of several
urinary protein biomarkers that serve as preclinical diag-
nostic biomarkers of drug-induced kidney injury including
KIM-1, clusterin, trefoil factor 3, and osteopontin [17].
These new biomarkers are altered before major functional
defects have occurred and signal specific renal damage
(KIM-1, Clu). Additional urinary protein biomarkers,
genes, and metabolites are being similarly evaluated for
inclusion as preclinical biomarkers of toxicity [18]. How-
ever, most of the in-life testing and evaluation of renal
toxicity and biomarker performance occur exclusively inmale animals. Thus, further investigation into female and
sex-related differences in urinary protein biomarkers
specifically expressed in the kidney is warranted.
Knowledge of the basal expression of these genes and
their normal, sex-dependent differences throughout the
life cycle in preclinical models will inform the evaluation
of these biomarkers and deepen our understanding of
kidney function. We report global gene expression
profiles of the kidney across the rat life cycle and the
sex-specific changes that may influence normal kidney
biology or underlie susceptibilities to adverse events.
Methods
Animal study
Male and female Fischer 344 (F344) rats were obtained
and housed as previously described [19] and housed
under AAALAC-approved conditions with a 12-h light/
dark cycle (0600–1800). The rats were housed two per
cage in standard polycarbonate cages with hardwood
chip bedding maintained at 23°C with a relative humidity
of approximately 50%. The rats were sacrificed at 2, 5, 6,
8, 15, 21 weeks (n = 6 per age group), 78 weeks (n = 8),
and 104 weeks (n = 6) of age. Females were not synchro-
nized for estrous cycle. Fischer rats were used due to their
frequent use for in-life bioassays in preclinical toxicology
studies. The rats were treated according to the National
Center for Toxicological Research Institutional Animal
Care and Use Committee guidelines.
Necropsy
The animals were sacrificed at the same circadian time for
each time point and euthanized through carbon dioxide
asphyxiation. The sections of the kidneys were collected
from rats aged 78 and 104 weeks for histological exami-
nation and placed in 10% neutral buffered formalin.
Standa paraffin embedding, sectioning, and hematoxylin
and eosin staining were performed for histopathological
examination of the 78- and 104-week kidney sections by a
staff board-certified pathologist.
RNA isolation
Total RNA was isolated from approximately 30 mg of
whole, homogenized, kidney tissue of independent animals
as previously described [19] using Qiagen RNeasy Mini Kit
(Qiagen Inc., Valencia, CA, USA) according to manufac-
turer’s protocol. The yield of the extracted RNA was deter-
mined spectrophotometrically by measuring the optical
density at 260 nm (Nanodrop-1000, Thermo Scientific,
Wilmington, DE, USA). The purity and quality of extracted
RNA were evaluated using the RNA 6000 LabChip and
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA, USA). The RNA samples with RNA integrity
numbers (RINs) greater than 8.0 were used for microarray
experiments with an average RIN of 8.5 for all samples.
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Whole genome microarray experiments (n = 4 for 2, 5, 6,
8, and 104-week males; n = 5 for 15, 21, and 78-week males
and 2, 5, 6, 8, 15, 21, 78, and 104 week females) were
completed for a total of 75 microarrays. Single color (Cy3)
Agilent Whole Rat Genome 4 × 44 K microarrays and
reagents were used according to manufacturer’s protocols
(Agilent Technologies, Santa Clara, CA, USA) using
500 ng of total RNA. An Agilent one-color spike-in kit was
used as a positive control. The arrays were scanned using
the Agilent High Resolution C Scanner (Agilent Technolo-
gies). The images were analyzed using Agilent’s Feature
Extraction software. A universal rat reference (URR) RNA
(Stratagene, Agilent Technologies) was labeled and incor-
porated into the array design to control for batch/day
effects during data processing. Pair-wise Pearson’s correla-
tions between un-normalized individual URR array inten-
sity values (F532-median) ranged from R = 0.955 to 0.991.
Full microarray data are available at Gene Expression
Omnibus with accession GSE47070.
Microarray data analysis
Microarray intensity data were uploaded to the
ArrayTrack™ database [20] and normalized using 75th-
percentile scaling without background subtraction. Rela-
tive fold-change values (individual values divided by the
averaged expression from all ages in both sexes) were
calculated on a per spot/feature basis. Following the
MAQC Consortium recommendations (MAQC Consor-
tium, 2006) for microarray data analysis, we employed a
combined approach using both fold change and statistical
criteria to determine differential gene expression. Intensity
values were log(2)-transformed prior to statistical analysis.
Filtering criteria, consisting of a 1.5-fold change and
ANOVA (FDR 5%) for age-related changes or 1.5-fold
change and pairwise t test (FDR 5%) for sex-related
changes, were used to define an initial set of differentially
expressed genes (DEGs). Applying these criteria to the
43,379 features on the Agilent microarrays resulted in 841
unique genes showing sex-related differences and 7,274
unique genes showing age-related differences for a total of
7,447 differentially expressed genes. The complete dataset
with annotations, fold changes, and statistical values is
available in Additional files 1 and 2: Table SA1 and
Table SA2. For brevity and consistency, the genes are
referenced by their official gene symbol as defined by
National Center for Biotechnology Information (NCBI).
Three-dimensional principal component analysis (PCA)
was performed on normalized intensity values of the 7,447
differentially expressed features in ArrayTrack (http://www.
fda.gov/ScienceResearch/BioinformaticsTools/Arraytrack/
default.htm). Default settings in the Ingenuity Pathway
Analysis (IPA, http://www.ingenuity.com/) for expression
dataset analyses were used for gene list functional analysis.Gene lists were uploaded using NCBI Entrez gene IDs
or gene symbols and submitted for IPA Core Analysis.
Ranked results from Top Networks, Bio-Functions,
Tox-Functions, and Canonical Pathways meeting minimal
p value <0.05 for each pathway containing at least three
focus molecules were queried for functional annotations
and over-represented pathways to facilitate the biological
interpretation of selected gene lists.
Microarray probe annotation update
The Agilent rat 4 × 44 K whole genome microarray con-
tains a total of 45,220 probes per array, 1,841 of which
are Agilent control probes. Therefore, 43,379 probes
were updated for the most current annotation. The
07Feb2007 version of Agilent annotation file (http://
www.chem.agilent.com/cag/bsp/gene_lists.asp) contained
23,644 probes with some annotation (Entrez gene ID or
symbol) corresponding to 16,801 unique Entrez gene IDs.
This initial annotation was updated using two sources: (1)
the Agilent 06Sept2011 version of annotation file down-
loaded from Agilent eArray website (https://earray.chem.
agilent.com/earray/) and (2) the annotation files down-
loaded from Rat Genome Database FTP website (ftp://rgd.
mcw.edu/pub/data_release/) as of February 6, 2012. The
Agilent probe ID was used as a common identifier where-
by the annotation of 28,552 probes representing 18,157
unique genes was attained for a net gain of 4,908
additional annotated probes (1,356 unique Entrez gene
IDs gained). The entire Entrez gene ID and their respec-
tive Symbols were verified from NCBI’s Gene webpage
(http://www.ncbi.nlm.nih.gov/gene). This newly annotated
list of probes is contained in Additional files 1 and 2: Table
SA1 and Table SA2.
Results
Male and female F344 rats aged 2 to 104 weeks (human
equivalent of 1–3 months to 70–80 years) were sacri-
ficed, and tissues collected at eight ages as previously
described [19]. The gene expression in the kidney was
measured using Agilent whole genome rat arrays. A
combined statistical and fold-change cutoff value was
used for the initial filtering criteria for both age and sex
differences. Filtering for differential expression by age
(ANOVA, FDR 5%, and fold change >1.5) resulted in
7,274 unique genes. Differential expression by sex (pair-
wise t test, FDR 5%, and fold change >1.5) resulted in 841
unique genes, showing sex difference at one or more ages,
for a combined total of 7,447 unique DEGs by either age
or sex in the kidney.
The 7,447 genes that met the filtering criteria were
used for principal component analysis. Figure 1A,B illus-
trates the results using different views. The top three
principal components (PCs) account for 32.5%, 13.8%,










Figure 1 Three-dimensional principal component analysis of differentially expressed genes. The 7,447 differentially expressed features
(FDR 5%; relative fold change >1.5) were used to assess the global view of each animal’s contribution to the life cycle expression profile. Each
sphere represents the composite expression profile of one animal according to the top three principal components plotted in three-dimensional
space (ArrayTrack). The spheres are colored by similar age group (N = 4 or 5). The spheres with black vertices indicate females, while those
without indicate males. Animals generally cluster together according to respective age and sex in an age-sequential pattern. Figure 1A, B shows
different views of the same plot: (A) highlights the age-related pattern, while (B) best displays the sex divergence in expression. The top three
principal components accounted for 32.5%, 13.8%, and 10.8% of the total variance.
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of individual animals to the global expression profiles of
the DEGs. Animals from the same age group and sex
tend to cluster tightly with each other. Each age group
appears in a pattern that is consistent with the sequen-
tial age in weeks (Figure 1A). PC1 accounts for variabi-
lity due to age as the age groups separate along the axis
parallel to PC1. Likewise, PC3 accounts for variability
due to sex as the sex differences between animals of the
same age group separate in space along the PC3 axis.
PC2 appears to capture variability due to adult animal
expression as 2- and 104-week groups differentiate from
8- to 21-week ones along the PC2 axis. Sex differences
in the age groups begin to be most noticeable by 6 weeks
of age (Figure 1B), are greatest at 15 and 21 weeks, and
decrease at 78 and 104 weeks. Together, these data
illustrate the relatively high reproducibility between
biological replicates in a discrete and continuous linear
pattern from young to old animals and among animals
of the same sex. It also suggests sex differences in
expression are most prominent during middle ages (8, 15,
and 21 weeks) while still showing differences in old age
(78 and 104 weeks).
The gene expression differences between males and
females during middle (8, 15, and 21 weeks) ages were
further analyzed for sex differences using Venn analysis.
The number of genes showing sex bias in expression
(sex bias = pairwise t test FDR 5% and relative fold
change >1.5 between sexes) was calculated at each age
group. The number of male-biased (male expression
levels higher than female) and female-biased (female
expression levels higher than male) genes was plotted
versus age (Figure 2A) to evaluate any patterns of uniquesex bias during the rate life cycle. Three notable patterns
were observed. First, 2-week-old animals exhibit 130
sex-biased genes prior to puberty. Secondly, those aging
8, 15, and 21 weeks exhibit the highest numbers of
male-biased and female-biased genes, compared to other
ages. Thirdly, sex-biased genes at 104 weeks exhibited
substantially more male-biased genes (87% of all sex-
biased genes) than female-biased genes.
The evaluation of sex-biased genes at 2 weeks revealed
130 genes exhibiting male or female bias according to
the criteria of 1.5-fold difference between males and
females. However, for 80 of these genes (62%), males
and females exhibit the same pattern of expression
between 2 and 5 weeks. In addition, for these 80 genes,
the age effect (fold change) between 2 and 5 weeks is
greater than the sex effect (fold change) at 2 weeks. This
means that age is having a greater influence on the
expression at these ages than sex for these 80 genes.
This suggests that the sex bias for more than half of the
130 two-week, sex-biased genes may be attributed to
differences in timing or development between males and
females rather than a true difference in gene expression.
The 130 sex-biased genes at 2 weeks are listed in
Additional file 3: Table SB. Because the middle ages (8, 15,
and 21 weeks) showed large sex differences (as visualized
in Figure 1B) and also comprise the most common ages
for in-life rodent testing for preclinical toxicity studies,
these three age groups were examined for genes showing
consistently sex-biased expression. Venn analysis was used
to identify 114 unique, sex-biased genes (Figure 3; see
Additional file 4: Table SC for lists of the genes) common
to all three age groups (i.e., Venn intersection). This set of
114 commonly sex-biased genes contains 69 female-
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Figure 2 Number of sex-biased genes per age group. The number of unique, differentially expressed genes exhibiting sex-difference in
expression (pairwise t test, FDR 5%, and 1.5 relative fold change between sexes) was calculated for each age group. The total number of sex-
biased genes (A) is divided into female- and male-biased genes per age group. 114 sex-biased genes common to 8-, 15-, and 21-week animals
(B) were plotted together in order to compare this list of robust sex differences accross all ages. Green, red, and blue lines represent numbers of
total, female-biased, and male-biased genes, respectively, at each age group.
8 wk






Sex Biased Genes Gene List Functional Analysis
Xenobiotic Metabolism Signaling, 
Fatty Acid Metabolism, Cancer, 
Fem > Male: 69 genes Protein Synthesis, Bupropion Degradation,
Endocrine System Development and
Function
Reproductive System Disease,
Male > Fem: 45 genes Molecular Transport, Nrf2-mediated
Oxidative Stress, Renal Necrosis/Cell Death
Figure 3 Venn diagram analysis of sex-biased genes during middle age. The intersection of genes exhibiting sex-biased expression at
middle age groups (8, 15, and 21 weeks) was calculated using Venn analysis. The genes commonly sex-biased (i.e., Venn intersection) were
divided into female- and male-specific gene lists, and functional analyses using Ingenuity Pathway Analysis was performed. Middle age groups (8,
15, and 21 weeks) showed relatively equal numbers of sex-biased genes. Sex-biased gene lists were analyzed for over-represented gene pathways
or networks.
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set showed mixed or confounding patterns of sex-biased
expression, meaning, all genes were consistently either
male- or female-biased at all three age groups.
These 69 and 45 sex-biased genes were subsequently
analyzed using Ingenuity Pathway Analysis for over-
representation of specific functional pathways or networks.
A consensus approach was used to review IPA’s Top
Networks, Top Bio Functions, Top Canonical Pathways,
and Top Tox Lists for repeated pathway or ontology terms
for each list of genes analyzed (Figure 3). The 69 female-
biased genes showed over-representation of xenobiotic me-
tabolism, protein synthesis, endocrine system development
and function, cancer, and fatty acid metabolism pathways.
The 45 male-biased genes showed over-representation of
reproductive system disease, molecular transport, Nrf2-
mediated oxidative stress, and renal necrosis and cell death
pathways. Thus, very different biology is reflected in these
two sex-biased gene lists. The 114 sex-biased genes
common to 8-, 15-, and 21-week animals were plotted
together (Figure 2B) in order to compare this list of robust
sex differences across all ages.
The examination of the sex-biased expression at
104 weeks revealed that 130 of the 152 sex-biased genes
(87%) were male-biased. Functional analysis of the 130
male-biased genes revealed over-representation of im-
mune response, inflammation response, immune cell traf-
ficking, cell-mediated inflammatory response, and T cell
receptor signaling pathways.
The functional categories found for the male-biased
gene expression pattern at 104 weeks of age suggested
the strong activation of an immune reaction. To verify
this at the cellular level, histopathological examination
of kidney tissue sections was performed, and a 2- and
1.5-fold increase (M > F, p < 0.01) in average severity
score for mononuclear cell infiltration was identified at
78 and 104 weeks, respectively (Figure 4). These histo-
pathological findings confirmed the sex-specific (M > F)A
Figure 4 Histopathological assessment of male-specific mononuclear
animals at 78 and 104 weeks were analyzed for presence and severity (sco
common indicator of immune response and inflammation. Male animals w
both 78 and 104 weeks. The figure shows kidneys of a female at 78 weeks
mononuclear cell infiltration, respectively.gene expression results that suggested increased im-
mune cell response. Because such immune response
may lead to the development of tissue fibrosis in older
males, renal fibrosis was also evaluated by histological
examination at 78 and 104 weeks. Fibrosis severity was
scored from 0 to 4, with 0 indicating absent and 4 indicat-
ing marked. Males showed more fibrosis than females at
these ages. Whereas female animals had an average fibrosis
severity score of 0.5 (range 0–1) and 1.5 (range 1–3) at 78
and 104 weeks, respectively, males had an average fibrosis
severity score of 2.1 (range 1–3) and 2.4 (range 1–4),
respectively.
Principal component analysis allows for the determin-
ation of those genes having the greatest influence on the
variability in one principal component by rank ordering
the loading values of that principal component. PC3
represents the variability within the dataset due to sex
differences (Figure 1B). Analysis of the loadings values
from PC3 revealed the top male- and female-biased
genes influencing the dataset in the PCA. The female-
biased genes having the largest influence on sex diffe-
rences are alcohol dehydrogenase 6 (Adh6), Col24a1,
and Akr1b7. The male-biased genes having the largest
influence in sex differences are solute carrier organic
anion transporter family member 1a1 (Slco1a1), dehy-
drogenase/reductase (SDR family) member 7 (Dhrs7),
Slc22a22, cytochrome P450, family 2, subfamily C, poly-
peptide 11 (Cyp2c11), and Mlc1. Examples of individual
gene expression profiles representing both the mag-
nitude of sex differences observed and their potential
relevance for kidney function are shown in Figure 5. The
expression of the genes for Slco1a1, solute carrier family
22 member 7 (Slc22a7), and ATP-binding cassette, sub-
family B (MDR/TAP), member 1B (Abcb1b), three
crucial renal transporters involved in drug uptake and ex-
cretion, exemplifies the sex differences present, especially
from 8 to 21 weeks. The maximum fold-change differ-
ence between the sexes ranges from 500 (male > female)B
cell infiltration. Kidney sections (H&E stained) from male and female
red 0–4 for absent to marked) of mononuclear cell infiltration, a
ere found to have higher severity scores on average than females at
(A) and a male at 78 weeks (B) exhibiting mild and moderate
Slco1a1
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Figure 5 Individual gene expression profiles exhibiting notable sex differences. Genes encoding Slco1a1, Slc22a7, Abcb1b, Cyp1a1, Cyp2c11,
Gstm1, Mmp7, Dhrs7, and Adh6 exhibit notable sex differences in life cycle gene expression in the rat kidney. Relative fold changes (microarray
data) are plotted; error bars represent SEM, n = 4 or 5. Females and males are indicated by dashed and solid lines, respectively. Averaged
expression levels (normalized fluorescence intensities) across all age groups and in both sexes are reported for each gene and have been scaled
to equal 1 in the plots.
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(female > male) for Abcb1b. Cytochrome P450, family
1, subfamily A, polypeptide 1 (Cyp1a1), Cyp2c11, and
glutathione S-transferase theta 1 (Gstm1) encode key
phase I and II drug metabolism proteins, with fold-
change expression differences between the sexes of ap-
proximately 6 (female > male), 250 (male > female), and
2 (male > female), respectively. Matrix metallopeptidase7 (Mmp7), an extracellular matrix maintenance enzyme
implicated in fibrosis, exhibits male-specific up-regulation
in the late age groups (eightfold). Dhrs7 and Adh6, coding
for two dehydrogenases, represent the most influential
sex-biased genes according to PCA loading value analysis,
with Dhrs7 showing a 500-fold male-biased expression
and Adh6 showing a 250-fold female-biased expression.
These examples illustrate the magnitude and timing of the
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pharmacological relevance during the life cycle.
Several gene products have been proposed recently for
use as kidney safety biomarkers [17,21], six of which
have been qualified by the FDA for use in preclinical
monitoring of disease- and drug-induced nephrotoxicity
(Table 1). The expression levels of five of the six genes
encoding qualified biomarkers exhibit sex differences of
twofold or greater and include kidney injury molecule 1
(Kim-1), clusterin (Clu), trefoil factor 3c (Tff3), osteo-
pontin (Spp1), and lipocalin 2 (Lcn2) (Figure 6). Notably,
Kim-1 exhibits about 23-fold difference at 8 weeks, the
most common age for in-life toxicity evaluations.
Fetuin A, a proposed renal biomarker, exhibits sex dif-
ferences in gene expression of over 600-fold at 2 weeks
(Table 1). These gene expression differences suggest
notable sex-related changes in protein expression which
may impact their use and utility. Taken together,
further evaluation of the role of sex differences in
renal biomarker discovery, qualification, and use is
warranted.
Discussion
Whole genome microarray gene expression data provide
a broad view of molecular activities in the rat kidney.
With an understanding that mRNA expression levels do
not necessarily correlate with protein expression levels,
the data are interpreted in view of both relative fold-Table 1 Current qualified and proposed kidney injury biomar
Kidney biomarkera Qualified Kidney injury location
Kim-1 (Havcr1) Yes Prox Tub
TFF3 (Tff3) Yes Prox Tub
NGAL (Lcn2) Yes Prox, Dist Tub
Osteopontin (Spp1) Yes Prox, Dist Tub, Lp Hnle
Clusterin (Clu) Yes Prox, Dist Tub
GST-α (Gsta2) Yes Prox Tub N
Fetuin-A (Ahsg) No Prox Tub
HGF (Hgf) No Prox Tub
GST-μ (Gstm1) No Dist Tub
Interleukin-18 (Il-18) No Prox Tub
GST-π (Gstp1) No Dist Tub N
NHE3 (Slc9a3r2) No Prox Tub, Lp Hnle N
Liver-type FABP (Fabp1) No Dist Tub N
CYR-61 (Cyr-61) No Prox Tub N
Heart-type FABP (Fabp3) No Dist Tub N
NAG (Hexb) No Prox Tub N
Netrin-1 (Ntn1) No Prox Tub N
Prox Tub proximal tubules, Dist Tub distal tubules, Lp Hnle loop of Henle.
aBiomarkers are referenced by their most common referenced human gene name fchange differences in expression as well as the mean
normalized intensity for each gene as a starting point for
assessing biological differences. Genes with higher mean
expression will provide more robust and reliable fold-
change estimates than weakly expressed transcripts. It is
understood that stressor-induced responses in gene
expression may exhibit different characteristics than
basal level gene expression with respect to the degree of
sex differences observed. Furthermore, genes showing
similar basal expression between sexes may exhibit sub-
stantial sex differences in response to stressors. Three-
dimensional principal component analysis provides a
global view of the relative impact of sex differences on
the variability of gene expression during the rat life
cycle. Even though PC3 accounts for less than 11% of
the variability of the differentially expressed genes, sex
differences are clearly evident between 8 and 21 weeks
of age (Figure 1B). The rank ordering of the loading
values for the principal components provides a starting
point in assessing which genes are most responsible for
the differences between sexes and organizes the genes
into male- and female-biased gene lists. For example,
Adh6 exhibits the largest influence on sex differences for
female-biased expression with an expression level of
more than 250-fold greater in females than in males.
Adh6 metabolizes a variety of substrates including
ethanol, retinol, hydroxysteroids, and lipid peroxidation
products. Adh6’s dramatic sex-specific expression in thekers
Sex bias Maximum fold-change
sex difference
Age of largest sex
difference (weeks)
F >M 23.5 8
M > F 9.7 21
M > F 3.7 78
F >M 2.7 8
M > F 2 104
o sex difference - -
M > F 600 2
F >M 2.4 2
M > F 2.1 21
M > F 1.5 104
o sex difference - -
o sex difference - -
o sex difference - -
o sex difference - -
o sex difference - -
o sex difference - -
o sex difference - -
ollowed by the official rat gene symbol in parentheses.
Havcr1 (Kim-1)
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Figure 6 Differential life cycle expression of genes encoding qualified and proposed kidney biomarkers. Genes encoding qualified renal
biomarkers Kim-1, Clu, Tff3, Lcn2, Spp1, and proposed renal biomarker Fetuin A show sex differences in expression from 2- to 600-fold in the
kidney. Relative fold changes (microarray data) are plotted; error bars represent SEM, n = 4 or 5. Females and males are indicated by dashed and
solid lines, respectively. Averaged expression levels (normalized fluorescence intensities) across all age groups and in both sexes are reported for
each gene and have been scaled to equal 1 in the plots.
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logical relevance is not clear.
The number of genes exhibiting sex-biased expression
varies across the eight ages with the exception of 5- and
78-week-old rats, when there is a substantial decrease
(Figure 2A). Two-week animals exhibit a considerable
number of sex-biased genes, given the general lack of
sex-hormone control. The notable drop in sex-biased
genes at 5 weeks of age may be a function of decreased
sex-specific signaling during the perinatal stage, shortly
after 2 weeks, and just prior to pubertal surges in steroid
hormones at 6 weeks which produce sexually mature
rats by 8 weeks of age [22]. This is consistent with the
rapid increase in sex-specific genes observed at 6 and
8 weeks of age. Prior to 104 weeks of age, there are
approximately equal numbers of male-biased and female-
biased genes at each age. The increase in the number of
genes whose expression is male-biased and the decrease
in the number of genes whose expression is female-biased
at 104 weeks appear to be explained by male-specific renal
fibrosis, inflammation, and immune cell infiltration [14].Immune response genes (Tgfb1, Il-18, Il-1b, Il-22, Il-9r,
and Il-2rg;) show male-biased, old-age-dependent increa-
ses in expression at 78 and 104 weeks of age. Histo-
pathological evaluation of the 78- and 104-week kidney
sections confirmed the male-biased presence of infiltrating
mononuclear cells, indicative of immune cell activity. The
higher level expression of these genes in males compared
to females may be responsible for the finding that females
show protection against age-related fibrosis and inflam-
mation [4].
Venn analysis, using the intersection of age-specific sex
differences, follows a consensus approach to minimize
false positives of genes truly exhibiting sex differences at
multiple consecutive age groups. However, this approach
does remove genes that would be bona fide sex-biased
only transiently at single age groups. Of the 69 common
female-biased genes from the 8- to 21-week age groups,
the top represented canonical pathway was the bupropion
degradation pathway that contains key enzymes cyto-
chrome P450 4B1 and 4F8 which, respectively, exhibit
greater than 8- and 16-fold increased expression in female
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chrome P450 1A1 also showed female-biased expression
(6.7-fold F >M) at 8–21 weeks of age, suggesting potential
sex differences in metabolism of polycyclic aromatic
hydrocarbons. Also represented between 8 and 21 weeks
were three UDP-glucuronosyltransferase family mem-
bers (Ugt2b17, Ugt2b4, and Ugt2b7) which are phase 2
conjugating enzymes with roles in metabolizing steroid
hormones (estrogen metabolites) and drugs or xenobi-
otics. Notably, Ugt2b7 is responsible for the metabolism
of morphine into an inactive form. The expression of
aldo-keto reductase family 1, member C1, which cata-
lyzes the conversion of progesterone into its inactive
form 20-alpha-hydroxy-progesteronem, was also found
to be female-biased. Bradykinin/kallidin pathway com-
ponent Kng2 (kininogen 2, kallidin, des-Arg10-kallidin,
bradykinin) integrates with the Ras (rat sarcoma gene
family) pathway in modulating normal renal function
and showed 9-fold higher expression in females than
males. Putative sex hormone regulation of kallikrein-
related gene expression may be linked to the human
pancreatic/renal kallikrein gene having potential estro-
gen and progesterone receptor binding sites and higher
urinary kallikrein excretion in women; renal kallikrein
and kallikrein mRNA levels are lowered after ovariec-
tomy in rats [23]. The 45 common, male-biased genes
were most represented by reproductive system disease-
related genes (Apoh, Esr1, F2, Prlr, Abcg2, Kifc1, Rasl12,
Gstm5), with estrogen receptor alpha being expressed >3-
fold higher in males than females between 8 and 21 weeks
of age. Steroid hormone metabolism enzymes 3-beta-
hydroxysteroid dehydrogenase 1 and 2 and estradiol-17-
beta dehydrogenase 1 all exhibited male-biased expression,
consistent with their roles in maintaining steroid levels in a
sex-specific manner.
Of the 74 cytochrome P450 enzymes present on the
Agilent rat microarray, 24 of them (32%) exhibit some
level of sex bias in expression, suggesting important
differences that may underlie drug-induced susceptibil-
ities. For instance, Cyp2c11 shows a >250-fold higher
expression in males compared to females, suggesting
sex-dependent susceptibility to certain drug or xeno-
biotic substrates of Cyp2c11. For example, limonene is a
substrate for Cyp2c11 [24] and has been shown to be a
kidney carcinogen in the male rat, but not in the female rat
[25]. Cyp2c11 is involved in the testosterone metabolism
pathway (formation of 2a- and 16a-hydroxytestosterone)
and is inhibited by Bisphenol A (BPA) in rat liver [26].
Despite the relatively high dose of BPA used to elicit this
effect in vitro, the sexually dimorphic expression of
Cyp2c11 may be important in mediating the potential
endocrine-disrupting health effects of BPA.
The effects of xenobiotic and drug exposures on the
handling of renal and extra-renal metabolites and theirtransport contribute to the major reasons for kidney
toxicity. Tissue or cellular levels of the molecular
transporters that mediate the selective filtering of these
molecules are linked to the kidney’s role in retaining or
excreting these metabolites. A recent review [27] lists six
(five uptake and one efflux) important kidney transporters
which have been reported to exhibit sex differences in ex-
pression in the rat kidney. Four of these six exhibited
matched, sex-biased expression at the mRNA level in the
current dataset including Slco1a1(OATP1A1), Slc22a7
(OAT2), Slc22a2(OCT2), and Abcg2(BCRP). The two
proximal tubule apical uptake transporters Slco1a1 and
Slc22a7 [27] showed opposite sex-biased gene expression.
Slco1a1 exhibited >500-fold, male-biased expression bet-
ween 6 and 21 weeks, while Slc22a7 shows up to 17-fold,
female-biased expression at the same ages (Figure 5).
These two transporters are responsible for the handling of
a significant proportion of prescribed drugs [1]. However,
an additional eight multidrug resistance-related trans-
porters were also shown to exhibit sex biases in expres-
sion, including Abcb1b (Figure 5), Abcc8, Slc22a3,
Slc21a4, Slco1a5, Slco1a6, and Slco1c1. Slco1a5 and
Slco1a6 are rodent-specific organic anion transporters that
show a fourfold or twofold male-biased expression differ-
ence, respectively, between 8 and 21 weeks of age, which
may limit or complicate the translation to clinical
relevance. However, the extrapolation of the sex-biased
expression of Slc21a4 to humans may be more promising.
Slc21a4(OAT-K1) is a kidney-specific organic anion trans-
porter that facilitates the basolateral uptake and clearance
of methotrexate, a drug prescribed for autoimmune dis-
eases as well as cancer chemotherapy. Our data show that
Slc21a4 exhibits male-biased expression (around twofold)
between 8 and 21 weeks of age. This sex-biased expression
pattern may provide explanation for clinical observations
of sex-dependent pharmacokinetics of methotrexate in
CNS-lymphoma patients [28]. In the clinic, females show
significantly decreased clearance of methotrexate com-
pared to males, which is consistent with lower expression
of this transporter in female rats. The functional impact of
mRNA expression differences between males and females
requires further investigation for genes encoding these
important transporters. However, our data present several
novel genes exhibiting sex-biased expression in the kidney
for further evaluation of functional differences between
males and females.
Sex differences in rat life cycle liver gene expression
have been previously published [19]. Identifying sex
differences between liver and kidney is of interest to
evaluate sex bias in drug metabolism and excretion. A
tissue comparison of sex-biased gene expression was
performed to identify such tissue-conserved sex diffe-
rences. The previously published liver data was re-analyzed
using the same criteria (pairwise t test, FDR 5%, and 1.5-
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kidney data. This analysis resulted in a total of 1,125 liver
genes showing sex-biased expression at one or more ages
compared to the 841 sex-biased kidney genes. There were
153 genes in common between the two tissues (Additional
file 5: Table SD). To evaluate if sex bias in gene expression
was present at the same ages in each tissue, a comparison
was performed at each age (Figure 7). As 8, 15, and
21 weeks exhibited the highest numbers of tissue-
conserved, sex-biased genes, a comparison of the three
ages was performed revealing ten genes in common be-
tween the three ages. These ten genes are: Adh6, Akr1b7,
Dhrs7, LOC690226, Odf3b, Prlr, Scml4, Tmed3, Trim24,
and Ust5r. It is interesting to note that LOC690226 is cur-
rently annotated as “similar to Dhrs7” but is located at a
unique locus on the same chromosome (Chromosome 6)
as Dhrs7. All genes exhibited the same sex bias between
liver and kidney except Prlr. In the kidney, Prlr shows
male-biased expression, whereas in the liver, Prlr shows
female-biased expression. It is unclear what influence these
tissue-conserved, sex-biased gene expression differences
may have on sex-specific susceptibility to adverse health ef-
fects or diseases. One previously published report [29]
compared sex-biased expression of drug metabolism-
related genes between liver and kidney in rats of 8 weeks
of age. Only six genes (Cyp2c6, Cyp2c11, Cyp2c12, Ugt1a8,
Ugt1a9, and Ahr) were reported as having conserved sex-
biased expression between liver and kidney. Of these six
genes, only Cyp2c11 was in common with the tissue-
conserved, sex-biased genes identified in the rat life cycle
studies. Cyp2c11 exhibits male-biased expression during
middle ages in both liver and kidney which has been well
characterized [30].Figure 7 Comparison of sex-biased genes between kidney and
liver. The number of sex-biased genes was calculated at each age
group for the kidney and compared to previously published data in
the liver [19]. The number of sex-biased genes common between
kidney and liver is displayed for each age group. A list of the 153
sex-biased genes common to both tissues is available in Additional
file 5: Table SD.The qualification of renal urinary proteins as preclin-
ical biomarkers of acute kidney injury has proceeded
mostly in the absence of female data [17]. Thus, the
analysis of potential sex-specific differences in biomarker
behavior or performance will benefit their use and applica-
tion. As previously reported, the age-specific nephroto-
xicity observed after cisplatin and gentamicin treatment in
male animals [31] correlated well with Havcr1(KIM-1)
expression levels in the kidney [19]; increasing levels of
nephrotoxicity correlated with increasing mRNA expres-
sion of KIM-1, depending on the animal age. The per-
formance of KIM-1 as a biomarker of such nephrotoxicity
for female animals might require further investigation
because mRNA expression of KIM-1 in female animals at
8 weeks shows >23-fold sex difference (F >M) (Figure 6;
Table 1). The finding of a large sex bias in the expression
of the KIM-1 gene (23-fold higher in females than in
males) cautions against direct extrapolation of the male
preclinical biomarker qualification data to females. The
genes coding for the qualified renal injury biomarkers Tff3
and Spp1 also exhibited sex-biased expression (9.7- and
2.7-fold sex bias, respectively; Figure 6, Table 1) at 8 to
21 weeks of age, the ages most commonly used for in-life
toxicology studies. These data provide comprehensive life
cycle coverage of sex-specific mRNA expression levels not
previously reported, which should provide sufficient
evidence for the investigation of further sex-specific func-
tional differences in kidney urinary protein biomarker
performance as well as the enzymes and molecular trans-
porters implicated in acute kidney injury and chronic
kidney disease.
Conclusions
These data provide evidence of sex-related differences in
the expression of genes in the kidney of rats over the life
cycle, from 2 weeks of age to 2 years of age. Many of the
genes showing sex-biased gene expression may impact
gene networks crucial to biological pathways, such as
xenobiotic metabolism (Cyp enzymes and drug trans-
porters), inflammation, and fibrosis that may underlie
sex-related susceptibilities. Gene-based biomarkers are
being evaluated and qualified for preclinical testing
because early diagnosis of drug-induced kidney injury is a
key consideration for pharmaceutical safety and decision-
making. Currently, proteins encoded by six genes (KIM-1,
Clu, Tff3, Spp1, Lcn2, and Gsta2) have been qualified by
the FDA for use as urinary biomarkers of kidney injury,
and additional markers (Table 1) continue to be evaluated.
We describe dramatic sex differences in the expression of
genes encoding these renal urinary biomarkers during the
life cycle, and consideration of these data should provide a
stronger basis for evaluating all renal biomarkers being
proposed. Together, these sex-related changes in kidney
gene expression during the rat life cycle expand current
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current and proposed safety biomarkers.
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